S. Kambhampati

发表

A. Verma, S. Kambhampati, S. Parmar, 2003, Cancer and Metastasis Reviews.

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.

K. Götze, P. Greenberg, A. Verma, 2015, The Lancet. Haematology.

CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells.

S. Kambhampati, O. Tawfik, Sushanta K Banerjee, 2008, Cancer research.

Activation of Protein Kinase Cδ by All-trans-retinoic Acid*

S. Minucci, A. Verma, S. Kambhampati, 2003, Journal of Biological Chemistry.

VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis.

S. Kambhampati, Sushanta K Banerjee, Snigdha Banerjee, 2008, Biochemistry.

Wnt / ß-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome

Mathijs, Ahrens, Michael G. Kharas, 2017 .

Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.

Michael G. Kharas, K. Hochedlinger, K. Pradhan, 2017, Cancer research.

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

D. Cherepanov, S. Kambhampati, R. Rifkin, 2020, Clinical Lymphoma Myeloma and Leukemia.

2-Methoxyestradiol Inhibits Barrett's Esophageal Adenocarcinoma Growth and Differentiation through Differential Regulation of the β-Catenin–E-Cadherin Axis

Suman Kambhampati, S. Kambhampati, Sushanta K Banerjee, 2010, Molecular Cancer Therapeutics.

CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma

D. V. Von Hoff, S. Kambhampati, Arnab Ghosh, 2019, Molecular Cancer Therapeutics.

CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2018, Leukemia research.

Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies

S. Kambhampati, U. Steidl, B. Will, 2016, Leukemia.

Boron chemicals in diagnosis and therapeutics.

A. Verma, S. Kambhampati, Sushanta K Banerjee, 2013, Future medicinal chemistry.

Allogeneic endometrial regenerative cells: An "Off the shelf solution" for critical limb ischemia?

Amit N. Patel, Hao Wang, S. Kambhampati, 2008, Journal of Translational Medicine.

A Primer on Chimera Associated Receptor T-Cells.

S. Kambhampati, Sumalatha Muthineni, K. Zink, 2021, Missouri medicine.

The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF–ERK signaling

S. Kambhampati, Sushanta K Banerjee, G. Maity, 2018, The Journal of Biological Chemistry.

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2015, Leukemia.

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

P. Vyas, C. Takimoto, S. Kambhampati, 2019, Blood.

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

J. Byrd, S. Kambhampati, K. Blum, 2009, British journal of haematology.

Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia

K. Bhalla, S. Kambhampati, J. McGuirk, 2013, Pharmacotherapy.

POEMS Syndrome and Small Lymphocytic Lymphoma Co-Existing in the Same Patient: A Case Report and Review of the Literature

S. Kambhampati, S. Mathur, A. A. Kumar, 2015 .

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

D. Faller, S. Kambhampati, L. Adès, 2021, Blood.

Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia — A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy

K. Götze, P. Greenberg, A. Verma, 2013 .

p38 in chronic myelogenous leukemia: a target and a possible biomarker

S. Kambhampati, 2009, Leukemia & lymphoma.

Myelodysplastic Syndrome with concomitant t(5;21)(q15;q22) and del(5)(q13q33): case report and review of literature.

S. Kambhampati, J. Woodroof, D. Persons, 2016, Stem cell investigation.

g by IFN- d Activation of Protein Kinase C

A. Verma, S. Kambhampati, L. Platanias, 2003 .

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.

P. Vyas, C. Takimoto, S. Kambhampati, 2020 .

Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

R. Collins, P. Greenberg, G. Gaidano, 2014 .

The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.

P. Vyas, C. Takimoto, S. Kambhampati, 2019, Journal of Clinical Oncology.

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.

J. Burke, K. Kolibaba, I. Flinn, 2021, The Lancet. Haematology.

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.

P. Vyas, R. Larson, S. Kambhampati, 2022, Journal of Clinical Oncology.

Hemopoietic Suppression in Aplastic Anemia Pathway Mediates Cytokine-Induced Mitogen-Activated Protein Kinase Signaling Cutting Edge: Activation of the p38

Amit Verma, S. Kambhampati, S. Uddin, 2002 .

Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia

O. Frankfurt, S. Kambhampati, H. Kantarjian, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.

Katie M. Reindl, S. Kambhampati, M. Orr, 2020, Molecular pharmaceutics.

HDAC inhibitors and chaperone function.

K. Bhalla, S. Kambhampati, W. Fiskus, 2012, Advances in cancer research.

Retinoic acid signaling pathways in development and diseases.

A. Verma, S. Kambhampati, D. Wallace, 2014, Bioorganic & medicinal chemistry.

Aberrant Epigenetic and Genetic Marks Are Seen in Myelodysplastic Leukocytes and Reveal Dock4 as a Candidate Pathogenic Gene on Chromosome 7q*

O. Abdel-Wahab, A. Melnick, Jinghang Zhang, 2011, The Journal of Biological Chemistry.

Growth factors involved in prostate carcinogenesis.

S. Kambhampati, P. V. Van Veldhuizen, K. Sengupta, 2005, Frontiers in bioscience : a journal and virtual library.

Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway

S. Kambhampati, Arnab Ghosh, A. Ray, 2018, BMC Cancer.

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

S. Kambhampati, R. Rifkin, J. Richter, 2017 .

Cysteine-rich 61-Connective Tissue Growth Factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced Signaling Protein-2 (WISP-2) Regulates MicroRNA-10b via Hypoxia-inducible Factor-1α-TWIST Signaling Networks in Human Breast Cancer Cells

M. Mayo, S. Kambhampati, A. De, 2011, The Journal of Biological Chemistry.

A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells

S. Kambhampati, L. Stehno-Bittel, R. Garimella, 2014, Leukemia & lymphoma.

2‐Methoxyestradiol modulates β‐catenin in prostate cancer cells: A possible mediator of 2‐methoxyestradiol‐induced inhibition of cell growth

S. Kambhampati, A. Dhar, P. V. Van Veldhuizen, 2008, International journal of cancer.

Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor.

S. Kambhampati, J. Baranda, A. Weston, 2006, Frontiers in bioscience : a journal and virtual library.

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

M. Bitzer, A. Verma, S. Kambhampati, 2008, Blood.

Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS. Commentary

M. Bitzer, A. Verma, S. Kambhampati, 2008 .

Cutting Edge: Activation of the p38 Mitogen-Activated Protein Kinase Signaling Pathway Mediates Cytokine-Induced Hemopoietic Suppression in Aplastic Anemia1

A. Verma, S. Kambhampati, L. Platanias, 2002, The Journal of Immunology.

Activation of Rac1 and the p38 Mitogen-activated Protein Kinase Pathway in Response to Arsenic Trioxide*

S. Minucci, A. Verma, S. Kambhampati, 2002, The Journal of Biological Chemistry.

p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion

S. Kambhampati, L. Platanias, R. Bergan, 2003, Oncogene.

Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy.

J. Reeves, I. Flinn, B. Cheson, 2020, Blood.

Signalling Pathways Activated by All-trans-Retinoic Acid in Acute Promyelocytic Leukemia Cells

A. Verma, S. Kambhampati, S. Parmar, 2004, Leukemia & lymphoma.

Differential regulation of the p70 S6 kinase pathway by interferon α (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells

S. Kambhampati, S. Parmar, L. Platanias, 2005 .

Differential regulation of the p 70 S 6 kinase pathway by interferon ( IFN ) and imatinib mesylate ( STI 571 ) in chronic myelogenous leukemia cells

S. Kambhampati, S. Parmar, L. Platanias, 2005 .

Activation of Protein Kinase Cδ by IFN-γ1

A. Verma, S. Kambhampati, L. Platanias, 2003, The Journal of Immunology.

Loss of WISP-2/CCN5 signaling in human pancreatic cancer: a potential mechanism for epithelial-mesenchymal-transition.

S. Kambhampati, S. Mathur, Gopal Dhar, 2007, Cancer letters.

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

J. Burke, J. Gribben, K. Kolibaba, 2020, Blood.

AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

P. Vyas, R. Larson, C. Takimoto, 2021 .

Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.

J. Burke, K. Kolibaba, I. Flinn, 2017 .

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

B. Skikne, S. Kambhampati, A. Oriol, 2020 .

Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019

S. Kambhampati, S. Ganguly, G. R. Mohyuddin, 2021, Leukemia & lymphoma.

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.

R. Collins, P. Greenberg, G. Gaidano, 2016, The Lancet. Oncology.

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

I. Flinn, P. Vyas, S. Kambhampati, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

miR-21 mediates hematopoietic suppression in MDS by activating TGF-b signaling

P. Kenny, Xiaohong Jing, W. Ju, 2013 .

HEMATOPOIESIS AND STEM CELLS miR-21 mediates hematopoietic suppression in MDS by activating TGF-b signaling

P. Kenny, Xiaohong Jing, W. Ju, 2013 .

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation

S. Kambhampati, A. Lichtenstein, Y. Efebera, 2015, British journal of haematology.

Inpatient hospitalization’s associated cost and mortality in myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the National Inpatient Sample

S. Kambhampati, G. R. Mohyuddin, B. Mcclune, 2020, Leukemia & lymphoma.

Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019

S. Kambhampati, M. Qazilbash, V. Chandrasekar, 2021, BMC cancer.

Calcium-induced Matrix Metalloproteinase 9 Gene Expression Is Differentially Regulated by ERK1/2 and p38 MAPK in Oral Keratinocytes and Oral Squamous Cell Carcinoma*

M. Stack, S. Kambhampati, L. Platanias, 2004, Journal of Biological Chemistry.

Role of additional novel therapies in myeloproliferative neoplasms.

K. Bhalla, S. Kambhampati, W. Fiskus, 2012, Hematology/oncology clinics of North America.

Activation of protein kinase C delta by IFN-gamma.

A. Verma, S. Kambhampati, L. Platanias, 2003, Journal of immunology.

Short-Term Soy Isoflavone Intervention in Patients with Localized Prostate Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

S. Kambhampati, J. Thrasher, J. Holzbeierlein, 2013, PloS one.

Pomegranate sensitizes Tamoxifen action in ER-α positive breast cancer cells

S. Kambhampati, I. Haque, Shreya Banerjee, 2011, Journal of Cell Communication and Signaling.

Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia

Huidong Shi, S. Kambhampati, P. Dandawate, 2015, Oncotarget.

Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.

S. Kambhampati, S. Parmar, L. Platanias, 2005, Blood.

signaling β miR-21 mediates hematopoietic suppression in MDS by activating TGF-

P. Kenny, Xiaohong Jing, W. Ju, 2013 .

Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia

J. Byrd, K. Bhalla, C. Austin, 2013 .

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

D. Cherepanov, S. Kambhampati, R. Rifkin, 2020, Clinical Lymphoma Myeloma and Leukemia.

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia

A. Shamas-Din, M. Minden, S. Kambhampati, 2016, Cancer medicine.

Comparison of Bone Marrow Biopsy Specimens Obtained Using a Motorized Device and Manual Biopsy Systems

S. Kambhampati, J. Woodroof, C. Glennon, 2018, Asia-Pacific journal of oncology nursing.

Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS)

S. Kambhampati, A. Yacoub, J. Mikhael, 2017, Blood Cancer Journal.

HAART- and AIDS-related lymphomas.

S. Kambhampati, A. Malani, S. Ganguly, 2006, Blood.

Randomized study of continuous high-dose lenalidomide , sequential azacitidine and lenalidomide or azacitidine in persons > /-65 years with newly-diagnosed acute myeloid leukemia

R. Vij, S. Kambhampati, R. Gale, 2017 .

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

J. Burke, J. Gribben, K. Kolibaba, 2021, Blood.

A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY

J. Reeves, I. Flinn, B. Cheson, 2019, Hematological Oncology.

Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2012 .

Activation of protein kinase C delta by all-trans-retinoic acid.

S. Minucci, A. Verma, S. Kambhampati, 2003, The Journal of biological chemistry.

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

D. Faller, S. Kambhampati, L. Adès, 2022, Blood advances.

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

S. Kambhampati, C. McMahon, G. Borthakur, 2022, Blood.

Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway

S. Kambhampati, Arnab Ghosh, A. Ray, 2018, BMC Cancer.

Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better

S. Kambhampati, G. R. Mohyuddin, B. Mcclune, 2020, Leukemia and Lymphoma.

Blast Phase Chronic Myelogenous Leukemia

S. Kambhampati, Benjamin Powers, 2022 .

A Second-Generation 2-Methoxyestradiol Prodrug Is Effective against Barrett's Adenocarcinoma in a Mouse Xenograft Model

S. Kambhampati, R. Rajewski, P. V. Van Veldhuizen, 2013, Molecular Cancer Therapeutics.

Allogeneic endometrial regenerative cells: An "Off the shelf solution" for critical limb ischemia?

Amit N. Patel, Hao Wang, S. Kambhampati, 2008, Journal of Translational Medicine.

miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.

M. Bitzer, S. Kambhampati, U. Steidl, 2011, Blood.

M. Mayo, S. Kambhampati, A. De, 2011, The Journal of Biological Chemistry.

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia

R. Vij, S. Kambhampati, R. Gale, 2017, Haematologica.

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

S. Kambhampati, H. Kantarjian, T. Kadia, 2018, Blood.